MC 4232

Drug Profile

MC 4232

Alternative Names: MC-1/lisinopril; MC-4232; Pyridoxal phosphate/lisinopril

Latest Information Update: 18 Aug 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medicure
  • Class Antihypertensives; Coenzymes; Dipeptides; Ischaemic heart disorder therapies; Picolines
  • Mechanism of Action ACE inhibitors; Purinergic P2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetic complications; Hypertension

Most Recent Events

  • 18 Aug 2014 Discontinued - Phase-II for Diabetic complications in Canada (PO)
  • 18 Aug 2014 Discontinued - Phase-II for Hypertension in Canada (PO)
  • 26 Sep 2005 Medicure has completed a phase II MATCHED trial in patients with diabetes and hypertension
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top